Literature DB >> 27890237

Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.

Neera Nathan1, Kim M Keppler-Noreuil2, Leslie G Biesecker2, Joel Moss3, Thomas N Darling4.   

Abstract

Somatic mutations in genes of the PI3K/PTEN/AKT/TSC/mTORC1 signaling pathway cause segmental overgrowth, hamartomas, and malignant tumors. Mosaicism for activating mutations in AKT1 or PIK3CA cause Proteus syndrome and PIK3CA-Related Overgrowth Spectrum, respectively. Postzygotic mutations in PTEN or TSC1/TSC2 cause mosaic forms of PTEN hamartoma tumor syndrome or tuberous sclerosis complex, respectively. Distinct features observed in these mosaic conditions in part reflect differences in embryological timing or tissue type harboring the mutant cells. Deep sequencing of affected tissue is useful for diagnosis. Drugs targeting mTORC1 or other points along this signaling pathway are in clinical trials to treat these disorders. Published by Elsevier Inc.

Entities:  

Keywords:  Mosaicism; Next-generation sequencing; PIK3CA-related overgrowth spectrum; PTEN hamartoma tumor syndrome; Proteus syndrome; Sirolimus; Tuberous sclerosis complex; mTORC1

Mesh:

Substances:

Year:  2017        PMID: 27890237      PMCID: PMC5130114          DOI: 10.1016/j.det.2016.07.001

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  80 in total

Review 1.  The challenges of Proteus syndrome: diagnosis and management.

Authors:  Leslie Biesecker
Journal:  Eur J Hum Genet       Date:  2006-08-02       Impact factor: 4.246

2.  The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.

Authors:  T Maehama; J E Dixon
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

3.  FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.

Authors:  L Groesser; E Herschberger; M Landthaler; C Hafner
Journal:  Br J Dermatol       Date:  2012-03-14       Impact factor: 9.302

Review 4.  Mosaicism in human skin. Understanding the patterns and mechanisms.

Authors:  R Happle
Journal:  Arch Dermatol       Date:  1993-11

5.  High rate of mosaicism in tuberous sclerosis complex.

Authors:  S Verhoef; L Bakker; A M Tempelaars; A L Hesseling-Janssen; T Mazurczak; S Jozwiak; A Fois; G Bartalini; B A Zonnenberg; A J van Essen; D Lindhout; D J Halley; A M van den Ouweland
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

6.  PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.

Authors:  Kim M Keppler-Noreuil; Jonathan J Rios; Victoria E R Parker; Robert K Semple; Marjorie J Lindhurst; Julie C Sapp; Ahmad Alomari; Marybeth Ezaki; William Dobyns; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2014-12-31       Impact factor: 2.802

Review 7.  When overgrowth bumps into cancer: the PTEN-opathies.

Authors:  Jessica Mester; Charis Eng
Journal:  Am J Med Genet C Semin Med Genet       Date:  2013-05       Impact factor: 3.908

Review 8.  Tuberous sclerosis.

Authors:  Paolo Curatolo; Roberta Bombardieri; Sergiusz Jozwiak
Journal:  Lancet       Date:  2008-08-23       Impact factor: 79.321

9.  Activating PIK3CA somatic mutation in congenital unilateral isolated muscle overgrowth of the upper extremity.

Authors:  Claudia Castiglioni; Enrico Bertini; Paulina Orellana; Cynthia Villarroel; Facundo Las Heras; Daniel Hinzpeter; Paola Paolinelli; Jorge A Bevilacqua; Karin Alvarez
Journal:  Am J Med Genet A       Date:  2014-06-26       Impact factor: 2.802

10.  Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.

Authors:  Daria C Loconte; Valentina Grossi; Cristina Bozzao; Giovanna Forte; Rosanna Bagnulo; Alessandro Stella; Patrizia Lastella; Mario Cutrone; Francesco Benedicenti; Francesco C Susca; Margherita Patruno; Dora Varvara; Aldo Germani; Luciana Chessa; Nicola Laforgia; Romano Tenconi; Cristiano Simone; Nicoletta Resta
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

View more
  33 in total

Review 1.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

2.  Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.

Authors:  Mei Liu; Yong Lin; Xian-Chao Zhang; Yu-Huan Tan; Yue-Liang Yao; Juan Tan; Xia Zhang; You-Hong Cui; Xindong Liu; Yan Wang; Xiu-Wu Bian
Journal:  Lab Invest       Date:  2017-07-31       Impact factor: 5.662

3.  Parental somatic mosaicism for CNV deletions - A need for more sensitive and precise detection methods in clinical diagnostics settings.

Authors:  Qian Liu; Justyna A Karolak; Christopher M Grochowski; Theresa A Wilson; Jill A Rosenfeld; Carlos A Bacino; Seema R Lalani; Ankita Patel; Amy Breman; Janice L Smith; Sau Wai Cheung; James R Lupski; Weimin Bi; Pawel Stankiewicz
Journal:  Genomics       Date:  2020-05-06       Impact factor: 5.736

4.  Pathogenetic insights from quantification of the cerebriform connective tissue nevus in Proteus syndrome.

Authors:  Neera R Nathan; Rachna Patel; Molly M Crenshaw; Marjorie J Lindhurst; Cara Olsen; Leslie G Biesecker; Kim M Keppler-Noreuil; Thomas N Darling
Journal:  J Am Acad Dermatol       Date:  2017-10-16       Impact factor: 11.527

5.  Phenotype and Surgical Treatment in a Case of Proteus Syndrome With Craniofacial and Oral Findings.

Authors:  Reinhard E Friedrich
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

6.  Prevalence and Impact of Underlying Diagnosis and Comorbidities on Chiari 1 Malformation.

Authors:  Brooke Sadler; Timothy Kuensting; Jennifer Strahle; Tae Sung Park; Matthew Smyth; David D Limbrick; Matthew B Dobbs; Gabe Haller; Christina A Gurnett
Journal:  Pediatr Neurol       Date:  2020-01-21       Impact factor: 3.372

Review 7.  Overgrowth syndromes - clinical and molecular aspects and tumour risk.

Authors:  Frédéric Brioude; Annick Toutain; Eloise Giabicani; Edouard Cottereau; Valérie Cormier-Daire; Irene Netchine
Journal:  Nat Rev Endocrinol       Date:  2019-05       Impact factor: 43.330

8.  Hypertrichotic patches as a mosaic manifestation of Proteus syndrome.

Authors:  Deeti J Pithadia; John W Roman; Julie C Sapp; Leslie G Biesecker; Thomas N Darling
Journal:  J Am Acad Dermatol       Date:  2020-02-07       Impact factor: 11.527

Review 9.  A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.

Authors:  Guillaume Canaud; Adrienne M Hammill; Denise Adams; Miikka Vikkula; Kim M Keppler-Noreuil
Journal:  Orphanet J Rare Dis       Date:  2021-07-08       Impact factor: 4.123

Review 10.  Pathogenic postzygotic mosaicism in the tyrosine receptor kinase pathway: potential unidentified human disease hidden away in a few cells.

Authors:  Irene Tiemann-Boege; Theresa Mair; Atena Yasari; Michal Zurovec
Journal:  FEBS J       Date:  2020-09-05       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.